Pacritinib Paves a “Unique Lane” of Treatment for Select ...

Pacritinib, a JAK2/IRAK1 inhibitor, received FDA approval for treating PET-MF and PPV-MF patients with low platelet counts, based on PERSIST-2 trial results showing significant spleen volume and symptom reduction. It offers a full-dose option for patients with severe thrombocytopenia, marking a significant advancement in myelofibrosis treatment.